The association of endothelin-1 levels with renal survival in polycystic kidney disease patients.
Adult
Aged
Biomarkers
/ blood
Case-Control Studies
Disease Progression
Endothelin-1
/ blood
Female
Glomerular Filtration Rate
Hemodynamics
Humans
Hypertension
/ blood
Kidney
/ physiopathology
Male
Middle Aged
Polycystic Kidney, Autosomal Dominant
/ blood
Prognosis
Renal Insufficiency, Chronic
/ blood
Risk Factors
Time Factors
Up-Regulation
ADPKD
Biomarkers
CKD
Endothelial dysfunction
Endothelin
Journal
Journal of nephrology
ISSN: 1724-6059
Titre abrégé: J Nephrol
Pays: Italy
ID NLM: 9012268
Informations de publication
Date de publication:
Feb 2019
Feb 2019
Historique:
received:
04
05
2018
accepted:
13
06
2018
pubmed:
20
7
2018
medline:
6
5
2020
entrez:
20
7
2018
Statut:
ppublish
Résumé
The prominent features of autosomal dominant polycystic kidney disease (ADPKD) are early development of hypertension, chronic kidney disease and cardiovascular problems. Thus, we aimed to investigate the role of endothelin, a vascular biomarker, in the clinical course of ADPKD, including renal and cardiovascular survival. In 138 patients with ADPKD and 28 healthy controls, we measured serum endothelin-1 (ET-1) levels by enzyme-linked immunosorbent assay (ELISA). Endothelium-dependent vasodilatation (flow-mediated dilatation, FMD) and endothelium-independent vasodilatation (nitroglycerin-mediated dilatation, NMD) of the brachial artery were assessed non-invasively with high-resolution ultrasound. Magnetic resonance imaging (MRI) was performed with a 1.5-T system, and total kidney volumes were calculated using mid-slice technique. To determine PKD1 and PKD2 genotype, we performed molecular and genetic tests involving the following steps: DNA isolation, next-generation sequencing (NGS) and data analysis. Endothelin levels and height-adjusted total kidney volumes (hTKV) significantly increased while the estimated glomerular filtration rate (eGFR) decreased across CKD stages 1-4. Hypertension was more frequent in ADPKD patients with high serum endothelin. At multivariate Cox analysis, endothelin level, PKD1 truncating mutation, hTKV, high-sensitive C reactive protein (hs-CRP) level and the presence of diabetes mellitus were associated with the risk of overall survival. Moreover, endothelin level, PKD1 truncating mutation, hTKV, age and presence of hypertension were associated with the risk of renal survival. Additionally, body mass index (BMI), FMD, PKD1 truncating mutation, endothelin and triglyceride levels were independently associated with hypertension. Increased serum endothelin levels independently predict hypertension in ADPKD. Serum endothelin levels are also associated with both renal and overall survival in patients with ADPKD.
Sections du résumé
BACKGROUND
BACKGROUND
The prominent features of autosomal dominant polycystic kidney disease (ADPKD) are early development of hypertension, chronic kidney disease and cardiovascular problems. Thus, we aimed to investigate the role of endothelin, a vascular biomarker, in the clinical course of ADPKD, including renal and cardiovascular survival.
METHODS
METHODS
In 138 patients with ADPKD and 28 healthy controls, we measured serum endothelin-1 (ET-1) levels by enzyme-linked immunosorbent assay (ELISA). Endothelium-dependent vasodilatation (flow-mediated dilatation, FMD) and endothelium-independent vasodilatation (nitroglycerin-mediated dilatation, NMD) of the brachial artery were assessed non-invasively with high-resolution ultrasound. Magnetic resonance imaging (MRI) was performed with a 1.5-T system, and total kidney volumes were calculated using mid-slice technique. To determine PKD1 and PKD2 genotype, we performed molecular and genetic tests involving the following steps: DNA isolation, next-generation sequencing (NGS) and data analysis.
RESULTS
RESULTS
Endothelin levels and height-adjusted total kidney volumes (hTKV) significantly increased while the estimated glomerular filtration rate (eGFR) decreased across CKD stages 1-4. Hypertension was more frequent in ADPKD patients with high serum endothelin. At multivariate Cox analysis, endothelin level, PKD1 truncating mutation, hTKV, high-sensitive C reactive protein (hs-CRP) level and the presence of diabetes mellitus were associated with the risk of overall survival. Moreover, endothelin level, PKD1 truncating mutation, hTKV, age and presence of hypertension were associated with the risk of renal survival. Additionally, body mass index (BMI), FMD, PKD1 truncating mutation, endothelin and triglyceride levels were independently associated with hypertension.
CONCLUSIONS
CONCLUSIONS
Increased serum endothelin levels independently predict hypertension in ADPKD. Serum endothelin levels are also associated with both renal and overall survival in patients with ADPKD.
Identifiants
pubmed: 30022320
doi: 10.1007/s40620-018-0514-2
pii: 10.1007/s40620-018-0514-2
doi:
Substances chimiques
Biomarkers
0
Endothelin-1
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
83-91Références
Torres VE, Harris PC, Pirson Y (2007) Autosomal dominant polycystic kidney disease. Lancet 369(9569):1287–1301
doi: 10.1016/S0140-6736(07)60601-1
pubmed: 17434405
Ecder T, Schrier RW (2001) Hypertension in autosomal-dominant polycystic kidney disease: early occurrence and unique aspects. J Am Soc Nephrol 12:1 94–200
Gabow PA (1993) Autosomal dominant polycystic kidney disease. N Engl J Med 329:3 32–342
doi: 10.1056/NEJM199307293290508
Torres VE, Harris PC (2009) Autosomal dominant polycystic kidney disease: the last 3 years. Kidney Int 76:149–168
doi: 10.1038/ki.2009.128
pubmed: 19455193
pmcid: 2812475
Chang M-Y, Ong ACM (2011) Endothelin in renal physiology and disease. Contrib Nephrol 172:200–209
doi: 10.1159/000328701
pubmed: 21894000
Yanagisawa M, Kurihara H, Kimura S et al (1988) A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332(6163):411–415
doi: 10.1038/332411a0
Kohan DE (2010) Endothelin, hypertension and chronic kidney disease: new insights. Curr Opin Nephrol Hypertens 19(2):134–139
doi: 10.1097/MNH.0b013e328335f91f
pubmed: 20051851
pmcid: 2912219
Hocher B, Thdne-Reineke C, Rohmeiss P et al (1997) Endothelin-l transgenic mice develop renal cysts, interstitial fibrosis and glomerulosclerosis but not hypertension. J Clin Invest 99:1380–1389
doi: 10.1172/JCI119297
pubmed: 9077548
pmcid: 507954
Lai X, Bacallao RL, Blazer-Yost BL, Hong D, Mason SB, Witzmann FA (2008) Characterization of the renal cyst fluid proteome in autosomal dominant polycystic kidney disease (ADPKD) patients. Proteomics 2(7–8), 1140–1152
pubmed: 20411046
Ong AC, Newby LJ, Dashwood MR (2003) Expression and cellular localisation of renal endothelin-1 and endothelin receptor subtypes in autosomal-dominant polycystic kidney disease. Nephron Exp Nephrol 93:e80
doi: 10.1159/000068518
pubmed: 12629276
Nakamura T, Ebihara I, Fukui M et al (1993) Increased endothelin and endothelin receptor mRNA expression in polycystic kidneys of cpk mice. J Am Soc Nephrol 4:1064–1072
pubmed: 7904485
Hocher B, Zart R, Schwarz A et al (1998) Renal endothelin system in polycystic kidney disease. J Am Soc Nephrol 9:1169–1177
pubmed: 9644626
Sakurai T, Yanagisawa M, Takuwa Y et al (1990) Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor. Nature 348:732–735
doi: 10.1038/348732a0
pubmed: 2175397
Arai H, Hori S, Aramori I, Ohkubo H, Nakanishi S (1990) Cloning and expression of a cDNA encoding an endothelin receptor. Nature 348:730–732
doi: 10.1038/348730a0
pubmed: 2175396
Chang MY, Parker E, El Nahas M, Haylor JL, Ong AC (2007) Endothelin B receptor blockade accelerates disease progression in a murine model of autosomal dominant polycystic kidney disease. J Am Soc Nephrol 18(2):560–569
doi: 10.1681/ASN.2006090994
pubmed: 17202412
Inker LA, Astor BC, Fox CH et al (2014) KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD. Am J Kidney Dis 63(5):713–735
doi: 10.1053/j.ajkd.2014.01.416
pubmed: 24647050
Levey AS, Stevens LA, Schmid CH, CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) et al (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150(9):604–612
doi: 10.7326/0003-4819-150-9-200905050-00006
pubmed: 19414839
pmcid: 2763564
Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18(6):499–502
pubmed: 4337382
Celermajer DS, Sorensen KE, Gooch VM et al (1992) Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 340(8828):1111–1115
doi: 10.1016/0140-6736(92)93147-F
pubmed: 1359209
Corretti MC, Anderson TJ, Benjamin EJ, International Brachial Artery Reactivity Task Force et al (2002) Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 39(2):257–265
doi: 10.1016/S0735-1097(01)01746-6
pubmed: 11788217
Bae KT, Tao C, Wang J, Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) et al (2013) Novel approach to estimate kidney and cyst volumes using mid-slice magnetic resonance images in polycystic kidney disease. Am J Nephrol 38(4):333–341
doi: 10.1159/000355375
pubmed: 24107679
Richards S, Aziz N, Bale S et al (2015) Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 17(5):405–423
doi: 10.1038/gim.2015.30
pubmed: 25741868
pmcid: 4544753
Ong ACM, Harris PC (2005) Molecular pathogenesis of ADPKD: the polycystin complex gets complex. Kidney Int 67:1234–1247
doi: 10.1111/j.1523-1755.2005.00201.x
pubmed: 15780076
Schrier RW, Brosnahan G, Cadnapaphornchai MA et al (2014) Predictors of autosomal dominant polycystic kidney disease progression. J Am Soc Nephrol 25(11):2399–2418
doi: 10.1681/ASN.2013111184
pubmed: 24925719
pmcid: 4214531
Di Iorio BR, Cupisti A, D’Alessandro C, Bellasi A, Barbera V, Di Lullo L (2018) Nutritional therapy in autosomal dominant polycystic kidney disease. J Nephrol. https://doi.org/10.1007/s40620-018-0470-x (Epub ahead of print)
doi: 10.1007/s40620-018-0470-x
pubmed: 30069677
pmcid: 6061255
Girardat-Rotar L, Puhan MA, Braun J, Serra AL (2018) Long-term effect of coffee consumption on autosomal dominant polycystic kidneys disease progression: results from the Suisse ADPKD, a Prospective Longitudinal Cohort Study. J Nephrol 31(1):87–94
doi: 10.1007/s40620-017-0396-8
pubmed: 28386880
Kocyigit I, Yilmaz MI, Unal A et al (2013) A link between the intrarenal renin angiotensinsystem and hypertension in autosomal dominant polycystic kidney disease. Am J Nephrol 38(3):218–225
doi: 10.1159/000354317
pubmed: 23988725
Kocyigit I, Eroglu E, Orscelik O et al (2014) Pentraxin 3 as a novel bio-marker of inflammation and endothelial dysfunction in autosomal dominant polycystic kidney disease. J Nephrol 27(2):181–186
doi: 10.1007/s40620-014-0045-4
pubmed: 24515315
Kocyigit I, Kaya MG, Orscelik O et al (2012) Early arterial stiffness and inflammatory bio-markers in normotensive polycystic kidney disease patients. Am J Nephrol 36(1):11–18
doi: 10.1159/000339440
pubmed: 22699414
Kocyigit I, Taheri S, Sener EF et al (2014) Endothelial nitric oxide synthase gene expression is associated with hypertension in autosomal dominant polycystic kidney disease. Cardiorenal Med 4(3–4):269–279
doi: 10.1159/000369105
pubmed: 25737691
pmcid: 4299286
Munemura C, Uemasu J, Kawasaki H (1994) Epidermal growth factor and endothelin in cyst fluid from autosomal dominant polycystic kidney disease cases: possible evidence of heterogeneity in cystogenesis. Am J Kidney Dis 24:561–568
doi: 10.1016/S0272-6386(12)80212-5
pubmed: 7942810
Giusti R, Neri M, Angelini D et al (1995) Plasma concentration of endothelin and arterial pressure in patients with ADPKD. Contrib Nephrol 115:118–121
doi: 10.1159/000424407
pubmed: 8585897
Chang MY, Ong AC (2011) Endothelin in polycystic kidney disease. Contrib Nephrol 172:200–209
doi: 10.1159/000328701
pubmed: 21894000
Schrier RW (2009) Renal volume, renin-angiotensin-aldosterone system, hypertension, and left ventricular hypertrophy in patients with autosomal dominant polycystic kidney disease. J Am Soc Nephrol 20:1888–1893
doi: 10.1681/ASN.2008080882
pubmed: 19696226
Hocher B, Kalk P, Slowinski T et al (2003) ETA receptor blockade induces tubular cell proliferation and cyst growth in rats with polycystic kidney disease. J Am Soc Nephrol 14:367–376
doi: 10.1097/01.ASN.0000042165.63601.65
pubmed: 12538737
Grantham JJ, Mulamalla S, Swenson-Fields KI (2011) Why kidneys fail in autosomal dominant polycystic kidney disease. Nat Rev Nephrol 7(10):556–566
doi: 10.1038/nrneph.2011.109
pubmed: 21862990
Chang M-Y, Ong ACM (2013) New treatments for autosomal dominant polycystic kidney disease. Br J Clin Pharm 76:524–535